Results 291 to 300 of about 3,067,072 (318)
Some of the next articles are maybe not open access.
[JAK Inhibitors in Rheumatology].
Deutsche medizinische Wochenschrift (1946), 2019In Germany, baricitinib and tofacitinib have been approved for the treatment of at least moderately active rheumatoid arthritis after the failure of conventional disease modifying anti-rheumatic drugs in 2017, and tofacitinib also for psoriatic arthritis and ulcerative colitis. Both baricitinib and tofacitinib can be taken orally and reversibly inhibit
openaire +2 more sources
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors
American Journal of Clinical Dermatology, 2023Kaitlynne N. Cunningham, D. Rosmarin
semanticscholar +1 more source
Beyond JAK inhibitor therapy in myelofibrosis
Hematology, 2013AbstractMyelofibrosis (MF), including primary MF, postpolycythemia vera MF, and postessential thrombocythemia MF, is a clonal stem cell disorder characterized by BM fibrosis, extramedullary hematopoiesis, and a variable propensity to transform into acute leukemia. Allogeneic stem cell transplantation is the only known cure for MF, but its applicability
openaire +2 more sources
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Nature Reviews RheumatologyZoltán Szekanecz +8 more
semanticscholar +1 more source
The role of JAK/STAT signaling pathway and its inhibitors in diseases
International Immunopharmacology, 2020Shuang Liu, Youzhi Wang
exaly
JAK‐inhibitors for dermatomyositis: A concise literature review
Dermatologic Therapy, 2021Aliza Paudyal, Xiaoyan Lyu
exaly